Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)

In the low-dose cohort with patients followed for three months after PLG0206 treatment, there were:

• No treatment-related adverse events and,
• No recurrent infections, in contrast to the historical reinfection rate of 44% at 90 days

PITTSBURGH–(BUSINESS WIRE)–Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial. At 90 days post-Debridement, Antibiotics, and Implant Retention (DAIR) surgery, there were no treatment-related adverse events reported in the low-dose cohort. Additionally, zero infection recurrences were observed in this subset of patients compared to 44% recurrence rate in historical controls as shown by Zhu, et.al in the Journal of Arthroplasty in 2021 at 90 days. Detailed analyses along with data from the high-dose cohort will be presented at conferences in the coming months.

“The results are striking,” said Dr. Javad Parvizi MD, FRCS, James Edwards Professor of Orthopedic Surgery at the Rothman Institute at Thomas Jefferson University Hospital, and advisor to Peptilogics’ clinical advisory board, adding “To see such a clear effect in these hard-to-treat acute hematogenous patients from the low dose group is quite encouraging. I am looking forward to seeing additional promising outcomes from this trial soon that would point to the possibility of PLG0206 transforming the treatment paradigm for PJIs.”

PLG0206 was previously evaluated in a Phase 1 clinical trial in healthy volunteers and appeared to be safe following intravenous administration. In the Phase 1b clinical trial, PLG0206 is being studied in patients undergoing DAIR for treatment of a PJI occurring after total knee arthroplasty (TKA). The trial is an open-label study with two cohorts of seven patients each, with single-dose escalating treatments of PLG0206 of 3 mg/mL or 10 mg/mL, as an irrigation, compared to historical controls with standard-of-care treatment. All reported adverse events and serious adverse events (SAEs) were classified as unrelated to PLG0206 except for one SAE (neurogenic knee pain) in the high-dose cohort which was classified as possibly related to PLG0206. Three of seven subjects reported a total of five adverse events after PLG0206 administration. In the high-dose cohort at 21 days post-treatment, three of the seven subjects reported a total of seven adverse events and one of seven subjects reported a serious adverse event 13 days after PLG0206 administration.

“PLG0206 was designed to have the potential to be a breakthrough approach to providing a curative solution for all PJI patients, so we were thrilled to share this exciting milestone with clinicians and researchers in the PJI community. Innovation in PJI treatment has been stagnant and ineffective, leaving patients to suffer through multiple major surgeries, often without a successful resolution,” said Jonathan Steckbeck, Chief Executive Officer of Peptilogics. “And since the total cost of care for each PJI patient is nearly $500,000, if PLG0206 is successful, we will be able to significantly improve the economics for hospitals and insurance companies who bear the cost of failure. We are on a mission to help alleviate this condition for good,” he added.

“With PLG0206, we are developing a potential curative therapeutic solution for PJI built on its broad spectrum and biofilm-disrupting, anti-microbial properties that lead it to rapidly kill all bacteria living in complex biofilms, including the persister cells that are responsible for resistance to standard antibiotic treatment. We are encouraged with the initial results from the low-dose cohort, and we eagerly await long-term data as well as data from the high-dose cohort,” said David Huang, MD, PhD, Chief Medical Officer at Peptilogics.

Disclaimer

Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by an award from Wellcome Trust (WT224842). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.

About PLG0206

PLG0206 is an investigational broad-spectrum, anti-bacterial and anti-biofilm peptide therapeutic currently in clinical development for the treatment of PJI. PLG0206 was designed with a unique mechanism of action that targets and disrupts bacterial membranes, allowing it to directly address the persistent bacterial pathogens within the biofilm that evade standard-of-care antibiotics. In both in vitro and in vivo non-clinical studies, PLG0206 has demonstrated best-in-class, rapidly bactericidal, broad-spectrum activity against a variety of pathogens including those identified by the World Health Organization and the Centers for Disease Control and Prevention as critical, urgent, or high-priority targets, regardless of resistance phenotype. PLG0206 has been granted Orphan Drug Designation for the treatment of PJI, has been designated as a Qualified Infectious Disease Product (QIDP), and has been granted Fast Track Designation by the US FDA.

About Periprosthetic Joint Infection (PJI)

More than seven million total joint replacements will be performed annually in the major markets (US, UK, EU, JP) by 2030. Following joint replacement, over 150,000 patients will develop a PJI, a serious life-threatening condition, which often necessitates continuous antibiotic usage, multiple high-risk surgical procedures, and implant removal requiring more than 300,000 surgeries with limited ability to resolve the infection. The current standard of care has up to a 60% failure rate, resulting in a substantial number of patient deaths, evidenced by a 25% five-year mortality rate.

About Peptilogics

Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation.

For more information about Peptilogics, visit Peptilogics or follow the company on Twitter and LinkedIn.

Contacts

Atul Deshpande

Chief Strategy Officer

Email: [email protected]